Strategic partnerships GenomeScan collaborates closely with leading clinical centers (Erasmus Medical Center and Leiden University Medical Center) and aims to partner with hospitals, academia, and global pharma/biotech companies, signaling ample cross-selling opportunities for integrated diagnostics, patient stratification, and translational research services.

Clinical scale capabilities With in-house ISO/IEC 17025 accredited NGS testing, GCLP/GLP-compliant workflows, and high-throughput sequencing platforms (NovaSeq 6000, PacBio Sequel), GenomeScan can support large clinical and preclinical studies, appealing to sponsors needing robust, compliant genetic testing and rapid turnaround.

Comprehensive service portfolio Offering whole exome sequencing, panel sequencing, transcriptomics, and epigenetics, plus patient stratification by NGS profiles and tailored reporting, the company provides end-to-end solutions for diagnostic development, biomarker discovery, and regulatory-ready data packages.

Accessible data tools Recent launches like the My Projects portal and robust bioinformatics pipelines indicate a focus on secure, transparent data access and project monitoring, presenting a selling point for sponsors seeking streamlined data collaboration and fast, interpretable results.

Growth and visibility Participation in industry events (Swiss Biotech Day 2024) and a noted partnership with proteomics leader Olink suggest ongoing market expansion, enabling up-sell opportunities into proteomics-enabled workflows and broader multi-omics programs.